In this review we summarize the principles of anti-metastatic therapy with selected serpin family proteins, such as pigment epithelial-derived factor (PEDF) and maspin, as well as inter α-trypsin inhibitor (IαIs) light chains (bikunin) and heavy chains (ITIHs). Case-by-case, antimetastatic activity may be dependent or independent of the protease-inhibitory activity of the corresponding proteins. We discuss the incidence of target deregulation in different tumor entities, mechanisms of deregulation, context-dependent functional issues as well as in vitro and in vivo target validation studies with transfected tumor cells or recombinant protein as anti-metastatic agents. Finally, we comment on possible clinical evaluation of these proteins in adjuvant therapy.

中文翻译：

---

基于Serpins和Interα-胰蛋白酶抑制剂的基于蛋白质的抗转移疗法的潜力。

在这篇综述中，我们总结了使用选定的丝氨酸蛋白酶抑制蛋白家族蛋白（例如色素上皮衍生因子（PEDF）和maspin，以及间α-胰蛋白酶抑制剂（IαIs）轻链（bikunin）和重链）进行抗转移治疗的原理（ITIH）。视情况而定，抗转移活性可以取决于或独立于相应蛋白质的蛋白酶抑制活性。我们讨论了在不同肿瘤实体中靶标失调的发生率，失调机理，上下文相关的功能问题以及以转染的肿瘤细胞或重组蛋白作为抗转移剂的体外和体内靶标验证研究。最后，我们评论了这些蛋白质在辅助治疗中的可能临床评估。